286 related articles for article (PubMed ID: 25981178)
21. Prevalence and Predictors of Metabolic Syndrome in People With Schizophrenia in Inpatient Rehabilitation Wards.
Yang CY; Lo SC; Peng YC
Biol Res Nurs; 2016 Oct; 18(5):558-66. PubMed ID: 27268516
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.
Mitchell AJ; Vancampfort D; Sweers K; van Winkel R; Yu W; De Hert M
Schizophr Bull; 2013 Mar; 39(2):306-18. PubMed ID: 22207632
[TBL] [Abstract][Full Text] [Related]
23. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia.
Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C
Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054
[TBL] [Abstract][Full Text] [Related]
24. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study.
Kraemer S; Minarzyk A; Forst T; Kopf D; Hundemer HP
BMC Psychiatry; 2011 Nov; 11():173. PubMed ID: 22044502
[TBL] [Abstract][Full Text] [Related]
26. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Chue P; Mandel FS; Therrien F
Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.
Ahmed M; Hussain I; O'Brien SM; Dineen B; Griffin D; McDonald C
Ir J Med Sci; 2008 Sep; 177(3):205-10. PubMed ID: 18461270
[TBL] [Abstract][Full Text] [Related]
28. Metabolic syndrome among psychiatric inpatients with schizophrenia in Indonesia.
Marthoenis M; Aichberger MC; Puteh I; Syahrial S; Schouler-Ocak M
Asian J Psychiatr; 2015 Jun; 15():10-4. PubMed ID: 25910596
[TBL] [Abstract][Full Text] [Related]
29. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study.
Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A
Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820
[TBL] [Abstract][Full Text] [Related]
30. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P
J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013
[TBL] [Abstract][Full Text] [Related]
31. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
32. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
33. Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort.
Xing M; Sheng J; Cui M; Su Y; Zhang C; Chen X; Fang Y; Cui D; Li Z
Curr Neuropharmacol; 2022; 20(10):1969-1977. PubMed ID: 35236263
[TBL] [Abstract][Full Text] [Related]
34. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder.
Ignjatović Ristić D; Cohen D; Obradović A; Nikić-Đuričić K; Drašković M; Hinić D
Nord J Psychiatry; 2018 Feb; 72(2):124-129. PubMed ID: 29125018
[TBL] [Abstract][Full Text] [Related]
35. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.
Kraal AZ; Ward KM; Ellingrod VL
Psychopharmacol Bull; 2017 May; 47(2):8-21. PubMed ID: 28626268
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.
Popović I; Ravanić D; Janković S; Milovanović D; Folić M; Stanojević A; Nenadović M; Ilić M
Srp Arh Celok Lek; 2015; 143(11-12):712-8. PubMed ID: 26946767
[TBL] [Abstract][Full Text] [Related]
37. Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?
Lin EC; Shao WC; Yang HJ; Yen M; Lee SY; Wu PC; Lu RB
Metab Brain Dis; 2015 Feb; 30(1):107-13. PubMed ID: 25034455
[TBL] [Abstract][Full Text] [Related]
38. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care.
Seow LS; Chong SA; Wang P; Shafie S; Ong HL; Subramaniam M
Compr Psychiatry; 2017 Apr; 74():196-203. PubMed ID: 28214752
[TBL] [Abstract][Full Text] [Related]
40. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
